Trial intelligence / Profile preview

Capmatinib + spartalizumab vs capmatinib + placebo in first-line MET exon 14–mutant NSCLC

jRCT2080225343Phase 2Completed

Sponsor

Novartis

Start

Aug 2020

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules